- Home
- GDYN vs PRME Comparison
GDYN vs PRME Comparison
Compare GDYN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | PRME |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.3M | 553.2M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GDYN | PRME |
|---|---|---|
| Price | $7.77 | $3.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $10.67 | $7.56 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 18.18 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | $4,632,000.00 |
| Revenue This Year | $10.16 | $7.06 |
| Revenue Next Year | $10.84 | $47.01 |
| P/E Ratio | $393.00 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $5.11 | $2.67 |
| 52 Week High | $10.21 | $6.94 |
Technical Indicators
Market Signals| Indicator | GDYN | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 53.27 |
| Support Level | $5.32 | $3.16 |
| Resistance Level | $8.02 | $3.60 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 58.02 | 63.24 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.